Summary of the Conference Call for Yaoshi Technology Company Overview - **Company**: Yaoshi Technology - **Industry**: Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Key Financial Metrics - **Revenue**: 920 million CNY, up 23.48% year-on-year [2][4] - **Net Profit**: 72.5 million CNY, down 26.54% year-on-year [2][4] - **Net Profit Excluding Non-recurring Items**: 59.6 million CNY, down 11.82% year-on-year [2][4] - **Operating Cash Flow**: 467 million CNY, up 240.62% year-on-year [2][4] - **Contract Liabilities**: 114 million CNY, up 103.27% year-on-year [2][4] - **Gross Margin**: Downward trend but Q2 showed a slight increase of 1.4 percentage points from Q1, stabilizing around 35%-45% [2][4][8] Business Performance and Strategy - **CDMO New Orders**: Increased by 19.88%, with large multinational pharmaceutical companies contributing 367 million CNY, up 69.73% [2][4] - **Clinical Projects**: Over 1,100 early clinical to Phase II projects and 53 Phase III and commercialization projects completed [2][4][16] - **Focus Areas**: Emphasis on quality and innovation, strategic customer focus, and enhancing service capabilities [3][6][28] - **New Business Development**: Rapid growth in new chemical entities such as peptides, ADC (Antibody-Drug Conjugates), and TPD (Targeted Protein Degradation) [3][18] Market Dynamics - **Price Competition**: Intense price competition in both domestic and international markets, with strategies to sacrifice some margins for order acquisition [10][11] - **Market Segmentation**: Revenue from large multinational clients increased to 40% of total revenue, with significant growth in European and Japanese markets [14][17] Future Outlook - **Growth Expectations**: Anticipation of maintaining growth trends in the second half of the year, driven by AI technology applications and collaborations with leading multinational companies [5][6] - **Capacity Expansion**: Plans to increase capacity with new leased facilities to accommodate around 300 chemists by late 2025 or early 2026 [18] - **Investment in AI**: Ongoing investment in AI technology for drug discovery and project management, with plans to enhance capabilities further [26][27] Additional Insights - **Production Capacity Utilization**: Current capacity utilization is at industry average levels of 60%-70%, with ongoing assessments to meet increasing order demands [7][8] - **Cash Reserves**: Strong cash flow and improved accounts receivable turnover, maintaining a healthy cash reserve without significant pressure [25] - **Regulatory Environment**: Monitoring potential future drug tariffs that could impact the industry, with proactive global expansion strategies in place [22][23] This summary encapsulates the key points from the conference call, highlighting the financial performance, strategic initiatives, market conditions, and future outlook for Yaoshi Technology.

Group 1: Financial Performance - The company achieved a revenue of 920 million yuan in the first half of 2025, representing a year-on-year growth of 23.48% [2] - The net cash flow from operating activities was 467 million yuan, an increase of 240.62% compared to the same period last year [3] - The gross profit margin has shown a slight improvement of 1.4 percentage points from Q1 to Q2, indicating a stabilization trend [3] Group 2: Strategic Focus and Business Development - The company is focusing on three key strategies: concentrating on strategic clients, enhancing technological innovation, and expanding new business growth areas [2] - There has been a 19.88% year-on-year increase in new orders for CDMO business [3] - Revenue from multinational pharmaceutical companies (MNCs) increased by 69.73% year-on-year, reflecting deepening collaborations [3] Group 3: Operational Efficiency and Cost Management - The company is maintaining a capacity utilization rate of 60%-70% in mature workshops, which is considered a reasonable industry level [4] - Cost control measures are being strengthened to balance between cost management and strategic development [3] - The company has implemented various cost-reduction and efficiency-enhancing measures since the second half of last year [5] Group 4: Future Outlook and Market Trends - The company anticipates continued revenue growth in the second half of the year, supported by a favorable order backlog and market demand recovery [4] - There is a plan to expand fixed asset investments to meet the growing demand for new molecular drugs [6] - The company is confident in stabilizing and gradually returning the gross profit margin to an ideal level [5] Group 5: AI and Technological Integration - The company has systematically integrated AI applications across multiple business areas, generating over 80 million novel molecular blocks [10] - AI tools are being utilized to enhance operational efficiency, particularly in project reporting and document processing [10] - Future plans include expanding AI investments and deploying automated laboratory and robotic equipment [10]

Core Insights - The company reported a revenue of 920 million yuan for the first half of the year, representing a year-on-year increase of 23.48%, while the net profit attributable to shareholders decreased by 26.54% to 72 million yuan [1] Group 1: Business Performance - The front-end business (drug research) generated revenue of 154 million yuan, down 7.59%, with block revenue at 136 million yuan (down 4.71%) and CRO revenue at 18 million yuan (down 24.69%) [2] - The back-end business (drug development and commercialization) achieved revenue of 765 million yuan, an increase of 32.27%, with block revenue at 217 million yuan (down 8.80%) and CDMO revenue at 548 million yuan (up 60.92%) [2] - The gross margin for the front-end business was 57.29%, down 7.45 percentage points, while the back-end business gross margin was 25.69%, down 8.30 percentage points [2] Group 2: Strategic Focus and Financial Management - The company is focusing on revenue scale expansion and nurturing strategic clients and key projects, leading to a higher increase in operating costs compared to revenue growth [2] - The company improved cash flow management, with net cash flow from operating activities totaling 467 million yuan, an increase of 240.62% [3] - Revenue from multinational corporations (MNCs) reached 367 million yuan, up 69.73%, enhancing business sustainability [3] Group 3: Future Outlook - The company anticipates a recovery in performance as the pharmaceutical investment and financing environment improves, with adjusted net profit forecasts for 2025-2027 being 172 million, 228 million, and 297 million yuan respectively [3] - The company is shifting its project focus towards the back-end, with over 1,100 early-stage projects and 53 phase 3 and commercialization projects serviced in the first half of the year [2]

Core Viewpoint - The financial performance of the company shows mixed results, with revenue growth but a significant decline in net profit, indicating potential challenges in cost management and operational efficiency [1][3]. Financial Performance Summary - Total revenue for the first half of 2025 reached 920 million yuan, a year-on-year increase of 23.48% compared to 745 million yuan in 2024 [1]. - Net profit attributable to shareholders was 72.5 million yuan, down 26.54% from 98.7 million yuan in the previous year [1]. - Gross margin decreased to 31.05%, down 24.05% year-on-year, while net margin fell to 7.88%, a decline of 40.51% [1]. - The company reported a significant increase in operating cash flow per share, which rose by 240.51% to 2.34 yuan [1]. Accounts Receivable and Cash Management - Accounts receivable amounted to 299 million yuan, representing a decrease of 25.27% from 400 million yuan in the previous year, but still high at 136.06% of net profit [1][5]. - The company improved cash management, leading to a 14.51% increase in cash and cash equivalents [3]. Cost Structure and Expenses - Total sales, management, and financial expenses were 136 million yuan, accounting for 14.77% of revenue, a decrease of 18.81% year-on-year [1]. - Operating costs increased by 44.0%, attributed to revenue growth and changes in business structure [3]. Production Capacity and Orders - The company maintains a production capacity utilization rate of 60-70%, which is considered reasonable for the industry [7]. - New orders have been increasing, with overseas orders accounting for 60-70% and domestic orders for 30-40% [7][8]. Investment and Future Outlook - The company has over 70 clinical phase III and commercialization projects, with a growing proportion of strategic clients contributing to future revenue [8]. - Analysts expect the company's performance in 2025 to reach 217 million yuan, with an average earnings per share of 1.09 yuan [5].

Core Insights - The company reported significant revenue growth but a decline in net profit, indicating challenges in profitability despite increased sales [1][8] Revenue and Profit Performance - Total revenue for the first half of 2025 reached 920 million yuan, a year-on-year increase of 23.48%, while net profit attributable to shareholders was 72.5 million yuan, down 26.54% [1] - In Q2 2025, total revenue was 465 million yuan, up 26.48% year-on-year, but net profit decreased by 25.4% to 36.7 million yuan [2] Financial Metrics - Gross margin decreased to 31.05%, down 24.05% year-on-year, and net margin fell to 7.88%, a decline of 40.51% [3] - Total selling, administrative, and financial expenses amounted to 136 million yuan, accounting for 14.77% of revenue, a decrease of 18.81% year-on-year [3] - Earnings per share were 0.36 yuan, down 28.0% year-on-year, while net asset value per share increased by 27.69% to 17.52 yuan [3] Accounts Receivable and Debt Situation - The company's accounts receivable were substantial, with accounts receivable amounting to 136.06% of the latest annual net profit [4] - Interest-bearing liabilities stood at 1.381 billion yuan, a slight decrease of 0.29%, with an interest-bearing asset-liability ratio of 24.98% [4] Cash Flow Improvement - Net cash flow from operating activities was 467 million yuan, a significant increase of 240.62% year-on-year, attributed to improved sales collection and monitoring of material payments [5] Main Business Composition - Revenue from drug development and commercialization accounted for 83.14% of total revenue, with a gross margin of 25.69% [6] - Revenue from drug research services was 154 million yuan, representing 16.72% of total revenue, with a higher gross margin of 57.29% [6] - International sales contributed 659 million yuan, or 71.65% of total revenue, while domestic sales were 261 million yuan, accounting for 28.35% [6] Development Review and Outlook - The company focuses on enhancing drug discovery and development efficiency through chemical and low-carbon technology innovations [7] - Revenue from large multinational pharmaceutical companies grew by 69.73% to 367 million yuan, while revenue from small and medium-sized biotech firms increased by 4.55% to 553 million yuan [7] - The company is strengthening its R&D and production capabilities in various fields, including TPD, peptides, oligonucleotide drugs, and ADC drugs [7] Summary - The company achieved notable revenue growth but faced declines in net profit and profitability metrics, highlighting challenges in cost control [8] - Attention is needed on accounts receivable and debt levels, although cash flow from operations showed significant improvement [8] - Continued investment in R&D and technology upgrades suggests a promising future outlook for the company [8]

Summary of Key Points Core Viewpoint - The 2024 A-share Secretary Data Report indicates that the total salary of A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan, highlighting the significant role of secretaries in connecting investors and listed companies [1][2]. Group 1: Overall Salary and Demographics - The total salary for A-share listed company secretaries in 2024 is 4.086 billion yuan, with an average annual salary of 754,300 yuan [1]. - Among the secretaries, those aged 40 and below constitute 43% of the market, while those aged 50 and above account for 22% [1]. - The educational background of secretaries shows that 34% hold a bachelor's degree, 52% have a master's degree, and 14% possess a doctoral degree [1]. Group 2: Industry-Specific Salary Insights - The average annual salary for secretaries in the pharmaceutical and medical service sector is 839,200 yuan [2]. - The distribution of salaries shows that 24% earn below 500,000 yuan, 48% earn between 500,000 and 1 million yuan, and 28% earn above 1 million yuan [2]. - The top three highest-paid secretaries are Gilbert Shing Chung Li from Kanglong Chemical with 1.9855 million yuan, Gao Dapeng from Zhaoyan New Drug with 1.7384 million yuan, and Xu Xiangke from Kailaiying with 1.6114 million yuan [2].

Core Insights - The report highlights that in 2024, the total salary of A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the medical and healthcare services sector is 839,200 yuan [2] - The distribution of salaries shows that 24% earn below 500,000 yuan, 48% earn between 500,000 and 1 million yuan, and 28% earn above 1 million yuan [2] - The top three highest-paid company secretaries are Gilbert Shing Chung Li from Kanglong Chemical with 1.9855 million yuan, Gao Dapeng from Zhaoyan New Drug with 1.7384 million yuan, and Xu Xiangke from Kailaiying with 1.6114 million yuan [2] Age and Education Distribution - Company secretaries aged 40 and below constitute 43% of the market, while those aged 50 and above account for 22% [1] - The educational background of company secretaries shows that 34% hold a bachelor's degree, 52% have a master's degree, and 14% possess a doctoral degree [1] - Among the doctoral degree holders, there are 7 individuals, with the only full-time doctoral company secretary in the industry being Cao Nai'en from Huaxia Eye Hospital [1]

外资态度来看，本期较上一季度持股减少的外资基金共计1个，即香港中央结算有限公司，持股减少占 比达0.61%。 公募基金方面，本期较上一期持股增加的公募基金共计1个，即南方中证1000ETF，持股增加占比达 0.14%。本期较上一季度新披露的公募基金共计2个，包括博道中证1000指数增强A、博时中证1000增强 ETF。本期较上一季未再披露的公募基金共计2个，包括长城中证500指数增强A、东方量化成长灵活配 置混合A。 2025年8月8日，药石科技(300725.SZ)发布2025年半年度报告。截至2025年8月07日，共有6个机构投资 者披露持有药石科技A股股份，合计持股量达1326.51万股，占药石科技总股本的6.64%。其中，机构投 资者包括南京诺维科思创业投资合伙企业(有限合伙)、河南省恒通博远创业投资合伙企业(有限合伙)、 香港中央结算有限公司、招商银行股份有限公司-南方中证1000交易型开放式指数证券投资基金、博道 中证1000指数增强A、博时中证1000增强ETF，机构投资者合计持股比例达6.64%。相较于上一季度， 机构持股比例合计下跌了0.66个百分点。 ...

南京药石科技股份有限公司 2025 年半年度报告 杨民民先生与南京诺维科思创业投资合伙企业（有限合伙）为一致行动人。 的说明 除上述情况以外，公司未知前 10 名股东之间是否存在关联关系或一致行动。 公司股东施亦珺通过普通证券账户持有公司股票 0 股，通过申万宏源证券有限 公司客 户信用交易担保证券账户持有公司股票 2,411,930 股，实际合计持有 2,411,930 股。 前 10 名普通股股东参与融资融 公司股东诸金荣通过普通证券账户持有公司股票 0 股，通过中国银河证券股份 有限公 券业务股东情况说明（如有） 司客户信用交易担保证券账户持有公司股票 1,252,772 股，实际合计持有 1,252,772 股。 持股 5%以上股东、前 10 名股东及前 10 名无限售流通股股东参与转融通业务出借股份情况 □适用 ?不适用 前 10 名股东及前 10 名无限售流通股股东因转融通出借/归还原因导致较上期发生变化 □适用 ?不适用 公司是否具有表决权差异安排 南京药石科技股份有限公司 2025 年半年度报告摘要 □是 ?否 控股股东报告期内变更 □适用 ?不适用 公司报告期控股股东未发生变更。 实际控制人 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 南京药石科技股份有限公司（以下简称"公司"）第四届董事会第八次会议于 会议通知已于2025年7月28日通过电子邮件等方式送达各位董事。会议由董事长 杨民民先生召集主持，应出席董事人数7人，实际出席董事人数7人。公司部分高 级管理人员列席会议。本次会议的召集、召开符合《中华人民共和国公司法》 证券代码：300725 证券简称：药石科技 公告编号：2025-047 债券代码：123145 债券简称：药石转债 南京药石科技股份有限公司 第四届董事会第八次会议决议公告 （以 下简称"《公司法》"）和《南京药石科技股份有限公司公司章程》等有关规定。 一、 董事会会议审议情况 会议在保证所有董事充分发表意见的前提下，以投票表决方式通过了以下议 案： 表决结果： 7 票同意， 0 票反对， 0 票弃权 报告>的议案》。 经审核，公司募集资金的存放与使用符合中国证监会、深圳证券交易所关于 上市公司募集资金存放和使用的相关规定，不存在募集资金存放和使用违规的情 形。 本议案已经公司董事会审计委员会 2025 年第四次会议审议通过。 ...